Related Experiment Video
Updated: Jul 8, 2026
10:49
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
18.2K
A Review of FLT3 Kinase Inhibitors in AML
Cristina Negotei1,2, Andrei Colita1,2, Iuliana Mitu2
1Department of Hematology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Journal of Clinical Medicine
|October 28, 2023
Summary
FLT3 gene mutations in acute myeloid leukemia (AML) increase relapse and mortality risks. FLT3 inhibitors and chemotherapy, like midostaurin, are vital for treating FLT3-mutated AML, improving patient outcomes.
Area of Science:
- Hematology
- Oncology
- Molecular Biology
Background:
- Acute myeloid leukemia (AML) is an aggressive cancer characterized by abnormal blood cell precursors.
- FLT3 gene mutations are common in AML, significantly increasing relapse rates and patient mortality, especially in older adults.
Purpose of the Study:
- To review current and emerging treatment strategies for acute myeloid leukemia patients with FLT3 mutations.
- To highlight the importance of FLT3 mutation screening and the role of targeted therapies.
Main Methods:
- Literature review of studies on FLT3 mutations in AML.
- Analysis of treatment outcomes for FLT3-inhibitor based therapies.
- Discussion of chemotherapy, transplantation, and maintenance strategies.
Main Results:
- FLT3-ITD and FLT3-TKD are the main mutation types, with FLT3-ITD being more prevalent.
- FLT3 inhibitors, such as midostaurin and gilteritinib, are essential for managing FLT3-mutated AML.
- Allogeneic hematopoietic cell transplantation (HCT) and maintenance therapy improve long-term survival.
Conclusions:
- Targeted FLT3 inhibition combined with chemotherapy and HCT offers improved outcomes for FLT3-mutated AML.
- Gilteritinib shows promise for relapsed or refractory cases.
- Ongoing clinical trials are crucial for developing novel and combination therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...